United Therapeutics Corp

詳細情報 United Therapeutics Corp 企業名

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

企業情報

企業コードUTHR

会社名United Therapeutics Corp

上場日Jun 17, 1999

設立日1996

最高経営責任者「CEO」Dr. Martine A. Rothblatt

従業員数1305

証券種類Ordinary Share

決算期末Jun 17

本社所在地1000 Spring St

都市SILVER SPRING

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号20910

電話番号13016089292

ウェブサイトhttps://www.unither.com/

企業コードUTHR

上場日Jun 17, 1999

設立日1996

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

666.42K

-0.06%

Mr. Paul A. Mahon, J.D.

Executive Vice President, General Counsel, Corporate Secretary

36.78K

--

Mr. Richard A. Giltner

Independent Director

19.38K

+11.27%

Prof. Nilda Mesa, J.D.

Independent Director

4.88K

-11.67%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

3.20K

--

Mr. Michael Benkowitz

President, Chief Operating Officer

2.65K

+2.76%

Mr. Christopher Patusky, J.D.

Lead Independent Vice Chairman of the Board

2.00K

-0.20%

Gov. Thomas G. (Tommy) Thompson, J.D.

Independent Director

--

Mr. Christopher A. Causey

Independent Director

--

Mr. James C. Edgemond

Chief Financial Officer, Treasurer

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

666.42K

-0.06%

Mr. Paul A. Mahon, J.D.

Executive Vice President, General Counsel, Corporate Secretary

36.78K

--

Mr. Richard A. Giltner

Independent Director

19.38K

+11.27%

Prof. Nilda Mesa, J.D.

Independent Director

4.88K

-11.67%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

3.20K

--

Mr. Michael Benkowitz

President, Chief Operating Officer

2.65K

+2.76%

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

データなし

地域別USD

会社名

収益

比率

United States

749.60M

94.36%

Rest of World

44.80M

5.64%

事業別

地域別

データなし

株主

更新時刻: Fri, May 16

株主統計

種類

株主統計

比率

BlackRock Institutional Trust Company, N.A.

9.93%

The Vanguard Group, Inc.

9.84%

Avoro Capital Advisors LLC

5.93%

State Street Global Advisors (US)

4.95%

Renaissance Technologies LLC

4.67%

Other

64.69%

株主統計

比率

BlackRock Institutional Trust Company, N.A.

9.93%

The Vanguard Group, Inc.

9.84%

Avoro Capital Advisors LLC

5.93%

State Street Global Advisors (US)

4.95%

Renaissance Technologies LLC

4.67%

Other

64.69%

種類

株主統計

比率

Investment Advisor/Hedge Fund

48.91%

Investment Advisor

36.17%

Hedge Fund

7.48%

Pension Fund

4.28%

Individual Investor

1.75%

Research Firm

1.52%

Bank and Trust

1.46%

Sovereign Wealth Fund

1.23%

Insurance Company

0.12%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

1315

46.61M

103.33%

-1.16M

2025Q1

1369

46.67M

103.49%

-1.81M

2024Q4

1344

46.07M

102.60%

-3.00M

2024Q3

1278

45.38M

101.97%

-7.63M

2024Q2

1219

48.02M

108.26%

-2.92M

2024Q1

1151

47.12M

106.59%

-2.41M

2023Q4

1127

46.52M

99.01%

-2.26M

2023Q3

1094

46.35M

98.80%

-3.96M

2023Q2

1068

46.82M

99.96%

-3.45M

2023Q1

1055

47.11M

101.08%

-1.09M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

BlackRock Institutional Trust Company, N.A.

4.48M

9.93%

+12.87K

+0.29%

Mar 31, 2025

The Vanguard Group, Inc.

4.44M

9.84%

+15.26K

+0.34%

Mar 31, 2025

Avoro Capital Advisors LLC

2.67M

5.93%

-85.30K

-3.09%

Mar 31, 2025

State Street Global Advisors (US)

2.23M

4.95%

+30.71K

+1.40%

Mar 31, 2025

Renaissance Technologies LLC

2.11M

4.67%

+17.60K

+0.84%

Mar 31, 2025

Wellington Management Company, LLP

2.03M

4.49%

-437.48K

-17.76%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.22M

2.71%

+85.70K

+7.53%

Mar 31, 2025

Fidelity Management & Research Company LLC

1.03M

2.29%

-283.67K

-21.55%

Mar 31, 2025

AQR Capital Management, LLC

908.45K

2.01%

-67.00K

-6.87%

Mar 31, 2025

LSV Asset Management

902.32K

2%

-6.40K

-0.70%

Mar 31, 2025

詳細を見る

295.520USD

United Therapeutics Corp

295.520

概要

企業名

金融